Respiratory delivery of theophylline by size-targeted starch microspheres for treatment of asthma

Journal of Microencapsulation

Volumn 26, Issue 8, 2009, Pages 701-710

  Momeni, Arash ^a   Mohammadi, Mohammad H ^a  

^a AMIRKABIR UNIVERSITY OF TECHNOLOGY   (Iran)

Author keywords

Asthma; Factorial design; Respiratory drug delivery; Starch microsphere; Theophylline

Indexed keywords

GLUTARALDEHYDE; MICROSPHERE; PHOSPHATE BUFFERED SALINE; THEOPHYLLINE;

ARTICLE; ASTHMA; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; ENCAPSULATION; INFRARED SPECTROSCOPY; MUCOADHESION;

ADMINISTRATION, INHALATION; ASTHMA; CROSS-LINKING REAGENTS; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GLUTARAL; MICROSPHERES; PARTICLE SIZE; STARCH; THEOPHYLLINE;

EID: 70449346692     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652040802685043     Document Type: Article

References (47)

1. Atyabi F, Manoochehri S, Moghadam SH, Dinarvand R. 2006. Cross-linked starch microspheres: Effect of cross-linking condition on the microsphere characteristics. Arch Pharm Res 29:1179-1186.
2. Bajpai AK, Bhanu S. 2007. Dynamics of controlled release of heparin from swellable crosslinked starch microspheres. J Mater Sci Mater Med 18:1613-1621.
3. Barnes PJ. 2003. Theophylline: New perspectives for an old drug. Am J Respir Crit Care Med 167:813-818.
4. Barnes PJ, Pauwels RA. 1994. Theophylline in the management of asthma: Time for reappraisal? Eur Respir J 7:579-591.
5. Bosquillon C, Lombry C, Preat V, Vanbever R. 2000. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J Contr Rel 70:329-339.
6. Bosquillon C, Rouxhet PG, Ahimou F, Simon D, Culot C, Preat V, et al. 2004. Aerosolization properties, surface composition and physical state of spray-dried protein powders. J Contr Rel 99:357-367.
7. Callens C, Remon JP. 2000. Evaluation of starch-maltodextrin-Carbopol- 974 P mixtures for the nasal delivery of insulin in rabbits. J Contr Rel 66:215-220.
8. Chawla V, Tiwary AK, Gupta S. 2000. Characterization of polyvinylalcohol microspheres of diclofenac sodium: Application of statistical design. Drug Dev Ind Pharm 26:675-680.
9. Cherdoud-Chihani A, Mouzali M, Abadie MJM. 2003. Study of crosslinking acid copolymer/DGEBA Systems by FTIR. J Appl Polym Sci 87:2033-2051.
10. Cryan SA. 2005. Carrier-based strategies for targeting protein and peptide drugs to the lungs. AAPS J 7:20-41.
11. Cushley MJ, Holgate ST. 1985. Bronchodilator actions of xanthine derivatives administered by inhalation in asthma. Thorax 40:176-179.
12. Delval F, Crini G, Bertini S, Morin-Crini N, Badot P, Vebrel J, Torri G. 2004. Characterization of crosslinked starch materials with spectroscopic techniques. J Appl Polym Sci 93:2650-2663.
13. Edwards DA, Hanes J, Caponetti G, Hirkach J, Ben-Jebria A, Eskew ML, et al. 1997. Large porous particles for pulmonary drug delivery. Science 276:1868-1871. (Pubitemid 27443665)
14. Eriksson L, Johansson E, Kettaneh-Wold N, Wikstrom C, Wold S. 2000. Design of experiments-Principles and applications. Stockholm: Learnways, AB.
15. Gonda I. 2004. Targeting by deposition. In: Hickey AJ, editor. Pharmaceutical inhalation aerosols technology. 2nd ed. Vol.134, New York: Dekker. pp 65-88.
16. Heyder J, Svartengren MU. 2001. Basic principles of particle behavior in the human respiratory tract. In: Bisgaard H, O'Callaghan C, Smaldone CG, editors. Drug delivery to the lungs. Vol.162, New York: Dekker. pp 21-45.
17. Horton GE. 1966. The value and safety of nebulised aminophylline in acute bronchial asthma. J Tenn Med Ass 59:239-244.
18. International Commission on Radiological Protection. Human respiratory model for radiological protection (ICRP Publication 66). Ann ICRP 1994; 24:1-120.
19. Köbrich R, Rudolf G, Stahlhofen W. 1994. A mathematical model of mass deposition in man. Ann Occup Hyg 38:15-23.
20. Kaliner MA, Barnes PJ, Persson CGA. 2001. Asthma: Its pathology and treatment, Vol.49. New York: Dekker. pp 178-180.
21. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. 1983. Mechanism of solute release from porous hydrophilic polymers. Int J Pharm 15:25-35.
22. Kramarenko MP. 1961. Treatment of bronchial asthma with euphyllin aerosols (preliminary report). Clin Med 39:110-112.
23. Kunal P, Banthia AK, Majumdar DK. 2006. Starch based hydrogel with potential biomedical application as artificial skin. Afr J Biomed Res 9:23-29.
24. Larionova NV, Kazanskaya NF, Larionova1 NI, Ponchel G, Duchene D. 1999. Preparation and characterization of microencapsulated proteinase inhibitor aprotinin. Biochemistry (Moscow) 64:857-862.
25. Lee SJ, Rosenberg M. 1999. Preparation and properties of glutaraldehyde cross-linked whey protein-based microcapsules containing theophylline. J Contr Rel 61:123-136.
26. Levy RJ, Schoen RJ, Levy JT, Nelson AC, Howard SL, Oshry LJ. 1983. Biologic determinants of dystrophic calcification and osteocalcin deposition in glutaraldehyde-preserved porcine aortic valve leaflets implanted subcutaneously in rats. Am J Pathol 113:142-155.
27. Magenheim B, Benita S. 1996. The use of factorial design in the development of nanoparticulate dosage forms. In: Benita S, editor. Microencapsulation: Methods and industrial applications. Vol.733, New York: Dekker. pp 93-131.
28. Merritt K. 1996. Systemic toxicity and hypersensitivity. In: Ratner BD, Hoffman AS, Schoen FJ, Lemons JE, editors. Biomaterials science: An introduction to materials in medicine 1st ed. California: Academic Press. pp 188-189.
29. National Institute of Health, Guidelines for the diagnosis and management of asthma. National asthma education program expert panel report. 1991. DHHS publication No. 91-3042.
30. Ogilvie RI, Fernandez PG, Winsberg F. 1977. Cardiovascular response to increasing theophylline concentrations. Eur J Din Pharmacol 12:409-414.
31. Park JH, Ye M, Park K. 2005. Biodegradable polymers for microencapsulation of drug. J Molecules 10:146-161.
32. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. 2001. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 163:1256-1276.
33. Peppas NA. 1985. Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv 60:110-111.
34. Rabbani NR, Seville PC. 2005. The influence of formulation components on the aerosolisation properties of spray-dried powders. J Contr Rel 110:130-140.
35. Reed CE, Offord KP, Nelson HS, Li JT, Tinkelman DG. 1998. Aerosol beclomethasone dipropionate spray compared with theophylline as primary treatment for chronic mild-to-moderate asthma. J Allergy Clin Immunol 101:14-23.
36. Scheuch G, Kohlhaeufl MJ, Brand P, Siekmeier R. 2006. Clinical perspectives on pulmonary systemic and macromolecular delivery. J Adv Drug Deliv Rev 58:996-1008.
37. Schulz H, Brand P, Heyder J. 2000. Particle deposition in the respiratory tract. In: Lenfant C, editor. Lung biology in health and disease. Vol.143, New York, Basel: Dekker. pp 229-290.
38. Shahin SM, Yamaura K. 2002. Preparation of theophylline hydrogels of atactic poly(vinyl alcohol)/NaCl/H2O system for drug delivery system. J Contr Rel 81:367-377. (Pubitemid 34607156)
39. Sinclair GW, Peppas NA. 1984. Analysis of non-Fickian transport in polymers using simplified exponential expressions. J Membrane Sci 17:329-331.
40. Smolensky MH, Lemmer B, Reinberg AE. 2007. Chronobiology and chronotherapy of allergic rhinitis and bronchial asthma. Adv Drug Deliv Rev 59:852-882.
41. Svartengren M, Svartengren K, Aghaie F, Philipson K, Camner P. 1999. Lung deposition and extremly slow inhalations of particles: Limited effect of induced airway constriction. Exp Lung Res 25:353-366.
42. Takeuchi H, Yamamoto H, Kawashima Y. 2001. Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Deliv Rev 47:39-54. (Pubitemid 32209231)
43. Thompson DC. 2004. Pharmacology of therapeutic aerosols. In: Hickey AJ, editor. Pharmaceutical inhalation aerosols technology. 2nd ed. Vol.134, New York: Dekker. pp 30-65.
44. Tuovinen L, Peltonen S, Liikola M, Hotakainen M, Lahtela-Kakkonen M, Poso A, et al. 2004. Drug release from starch-acetate microparticles and films with and without incorporated --amylase. Biomaterials 25:4355-4362.
45. Vanbever R, Mintzes JD, Wang J, Nice J, Chen D, Batycky R, et al. 1999. Formulation and physical charechterization of large porous particles for inhalation. Pharm Res 16:1735-1742.
46. Yano Y, Yoshida M, Hoshino S, Inoue K, Kida H, Yanagita M, Takimoto T, Kumagai T, Osaki T, Tachibana I. 2006. Anti-fibrotic effects of theophylline on lung fibroblasts. Biochem Biophs Res Commun 341:684-690.
47. Zhang WF, Chen XG, Li PW, He QZ, Zhou HY. 2008. Preparation and characterization of theophylline loaded chitosan/b-cyclodextrin microspheres. J Mater Sci Mater Med 19:305-310.